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The proarrhythmic effects of class IA antiarrhythmic
drugs were prospectively evaluated during programmed
ventricular stimulation in 24 consecutive patients with
frequent ventricular premature beats whose baseline
study, performed while no antiarrhythmic drugs were
being taken, showed no inducible sustained ventricular
arrhythmias. No patient had nonsustained (>5 beats) or
sustained ventricular tachycardia by history or baseline
24 hour ambulatory electrocardiographic monitoring.
Sequential stimulation studies using up to three extra -
stimuli were performed after administration of procain-
amide, quinidine and disopyramide on different days.
Proarrhythmlc response was defined as induction of one
or more of the following: 1) sustained monomorphic ven-
tricular tachycardia; 2) sustained polymorphic ventric-
ular tachycardia; 3) ventricular fibrillation; 4) repro-
ducibly inducible nonsustained monomorphic ventricu-
lar tachycardia.
During 55 antiarrhythmic drug trials (24 of procain-
amide, 21 of quinidine , 10 of disopyramide) in the 24
patients, 6 patients had a proarrhythmic response: sus-
tained monomorphic ventricular tachycardia in 3, ven-
tricular fibrillation in 2, nonsustained monomorphic
ventricular tachycardia in 1. Thus, 11% of drug trials
Antiarrhythmic drugs have the capacity to produce ventric-
ular arrhythmias or aggravate existing arrhythmias (1-7) .
Recentl y, programmed ventricular stimulation has been used
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resulted in a proarrhythmic response and 25% of pa-
tients had a proarrhythmic response to one of the drugs
tested. A proarrhythmic response to one drug did not
predict a similar response to another drug of the same
class. The 6 patients with a proarrhythmic response did
not differ significantly from the other 18 patients with
regard to underlying heart disease, electrocardiographic
or baseline 24 hour ambulatory electrocardiographic
characteristics; however, they did have a higher inci-
dence of digoxin usage (p < 0.02), a shorter baseline
right ventricular effective refractory period (p < 0.01)
and a smaller increment in effective refractory period
during antiarrhythmic drug testing (p = 0.06). Two of
these six patients had cllnical occurrence of sustained
ventricular arrhythmias while taking an antiarrhythmic
agent. All others have continued to do well during a
mean follow-up period of 9 ± 0.8 months.
It is concluded that antiarrhythmic agents may in-
duce ventricular tachyarrhythmias in patients with ven-
tricular premature beats but no prior ventricular tachy-
cardia, and this should be taken into consideration when
treating patients with ventricular arrhythmias of uncer-
tain prognostic significance.
(J Am Coll CardioI1987;9:389-97)
to establ ish direct evidence for possible antiarrhythmic drug-
induced sudden cardiac death (8) . In three previous studies
(9- 11) using programmed ventricular stimulation in patients
with a history of malignant ventricular tachyarrhythmias,
proarrhythmic responses to antiarrh ythmic drugs occurred
in about 15% of the studied patients. However, there are
few data on how frequently antiarrhythmic drugs induce
such responses in patients who have ventricular premature
beats but no prior history of malignant ventricular tachyar-
rhythmias.
In this study , we prospectively performed serial elec tro-
physiologic drug testing in patients with ventricular pre-
mature beats who had no evidence of sustained ventricular
arrhythmias in order to I) define the incidence of antiar-
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rhythmic drug-induced arrhythmias during programmed
ventricular stimulation; and 2) determine whether a proar-
rhythmic response to one class 11\ antiarrhythmic drug pre-
dicts a similar response to another drug of the same class .
Methods
Study patients. Between September 1984and April 1985,
37 patients were referred to the electrophysiology/arrhyth-
mia service of the Section of Cardiology for evaluation of
frequent symptomatic ventricular premature beats, arid they
were screened for the study. None of them had a prior history
of sustained ventricular tachycardia or cardiac arrest. Ven-
tricular premature beats were not related to any identifiable
acute precipitating factor or recent «4 months) myocardial
infarction and they occurred in the absence of antiarrhythmic
drug therapy. Thirteen of the 37 patients were excluded
because of the following predetermined exclusion criteria:
I) history of syncope (4 patients); 2) presence of sponta-
neous ventricular tachycardia (>5 beats) during 24 hours
of ambulatory electrocardiographic monitoring while taking
no antiarrhythmic drugs (3 patients) ; and 3) induction of
sustained ventricular tachycardia or ventricular fibrillation
during the baseline electrophysiologic study (6 patients).
The remaining 24 consecutive consenting patients formed
the study cohort.
There were 15 men and 9 women ranging in age from
24 to 77 years (mean 56 ± 4). Clinical diagnoses included
coronary artery disease in 6 of the 24 patients, 5 of whom
had previous myocardial infarction, congestive cardio-
myopathy (6 patients), hypertensive heart disease (4 pa-
tients) , valvular heart disease (4 patients) and no demon-
strable heart disease (4 patients). Twelve patients had mild
to moderate congestive heart failure (New York Heart As-
sociation functional classes II and III). Cardioactive med-
ications included diuretics in 13 patients, digoxin in 6 pa-
tients, nitrates in 12, and calcium channel blocking agents
in 2 patients ; these medications were continued throughout
the study . Antiarrhythmic drugs (five patients) and beta-
adrenergic blocking agents (two patients) were discontinued
48 hours before ambulatory electrocardiographic monitor-
ing. No patient was receiving amiodarone.
Protocol. Informed consent was obtained from each pa-
tient. All patients underwent baseline 24 hour ambulatory
electrocardiographic monitoring and programmed ventric-
ular stimulation while taking no antiarrhythmic drugs. Sub-
sequently, serial electrophysiologic studies were performed
with procainamide (24 trials) , quinidine (21 trials) or di-
sopyramide (10 trials) on three different days separated by
a 24 hour washout period . In 23 patients, procainamide was
administered intravenously , immediately after completion
of baseline programmed ventricular stimulation, at a dose
of 15 mg/kg body weight (infusion rate, 50 mg/min) fol-
lowed by a constant infusion at 3 mg/min; repeat study was
performed 10 minutes after starting the constant infusion.
In one patient , procainamide (500 mg) was administered
orally every 4 hours for seven doses . In all trials with quin-
idine and disopyramide , these drugs were administered or-
ally every 6 hours for at least five doses (quinidine sulfate ,
300 mg; disopyramide, 150 mg). At the end of each elec-
trophysiologic drug trial , a serum level of the given anti-
arrhythmic drug was obtained . At any time during the serial
antiarrhythmic drug testing, patients could voluntarily with-
draw and be managed in the usual clinical fashion.
All three drugs were tested in 9 patients, two drugs in
13 patients (procainamide and quinidine in 12, procainamide
and disopyramide in I) and procainamide alone was tested
in 2 patients. Disopyramide was not tested in all 12 patients
with a history of congestive heart failure. The duration of
drug testing averaged 7 days and a total of 79 electrophys-
iologic studies were performed in the 24 patients (average
3.3 studies/patient). During that time serum potassium level
was normal in all patients (range 3.8 to 4.7 mfq/liter) , and
in patients taking digoxin the serum digoxin level ranged
from 0.3 to 0.9 ng/ml. On completion of the study, patients
were followed up in the outpatient clinic at intervals of 1
to 3 months .
Programmed ventricular stimulation. The study was
performed with the patient in the postabsorptive and non-
sedated state. For the baseline study, a 6F quadripolar elec-
trode catheter was introduced percutaneously into the sub-
clavian vein under local anesthesia with I% lidocaine. In
no patient did the amount of lidocaine administered exceed
5 mI. The catheter was advanced to the right ventricular
apex and then the outflow tract. After completion of baseline
programmed ventricular stimulation, this electrode catheter
was left in place for subsequent serial studies. The external
portion of the catheter was protected by a sterile sleeve to
allow further manipulation .
The stimulation protocol consisted of the following: 1) 8
to 10 beat burst pacing at the right ventricular apex begin-
ning at a cycle length of 500 ms and decrementing to a
cycle length of 280 ms; 2) one , two and three extrastimuli
delivered to the right ventricular apex during ventricular
overdrive pacing at two different cycle lengths. The right
ventricle was driven with a pacing train of five.beats at a
cycle length of 500 ms and again at a cycle length of 400
ms with an intertrain interval of 4 seconds; and 3) the pro-
tocol outlined in steps 1 and 2 was repeated at the right
ventricular outflow tract. The end point for the stimulation
protocol was induction of sustained ventricular tachycardia,
ventricular fibrillation or completion of the protocol. Bipolar
electrograms were filtered (30 to 500 Hz), displayed on a
memory oscilloscope together with surface electrocardio-
graphic leads V I , I and aVF and recorded on a strip chart
recorder (VR-12, E for M/Honeywell) at a paper speed of
25 to 50 mm/s, Data were also recorded on a 12 channel
frequency modulated tape recorder (Honeywell 5600E) for
later replay and analysis . Baseline RR interval, QRS du-
ration and QT interval were recorded at a paper speed of
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Table 1. Frequency of Proarrhythmic Responses in 24 Patients
39\
Drug
Procai nam ide
Quinid ine
Disopyramide
Total
*Mean ± SEM.
No. of
Trials
24
21
10
55
Proarrhythmic
Responses (';0
1(10%)
6( 11 %)
Drug Level"
(J.Lg/ml )
(range)
8.7 ± 0.6
13.6 to 14.3)
2.9 ± 0.4
W.K to 6.K)
4.0 ± 0 .5
(2.5 to 7. I )
50 mm/s. The corrected QT interval (QTc) was calculated
according to Bazett's method.
The heart was paced by means of a programmable stim-
ulator (Bloom Associates Ltd.) that delivered square wave
stimuli of 1.5 rns duration at twice diastolic threshold (al-
ways :s 1.5 rnA).
Definitions. Ventricular tachycardia was defined as a
tachycardia of ventricular origin with a cycle length ranging
between 200 and 500 ms. Sustained ventricular tachycardia
was defined as a ventricular tachycardia that lasted longer
than 30 seconds or required an intervention (overdrive pac-
ing or cardioversion) for hemodynamic compromise. Non-
sustained ventricular tachycardia was defined as a tachy-
cardia that lasted from six beats to 30 seconds and terminated
spontaneously. Ventricular fibrillation was defined as or-
ganized or disorganized ventricular activity with a cycle
length of less than 200 rns requiring immediate defibrilla-
tion.
Criteria defining a proarrhythmic response during
programmed ventricular stimulation. An antiarrhythmic
drug was considered to have caused a proarrhythmic re-
sponse if one or more of the following arrhythmias were
induced: I) sustained monomorphic ventricular tachycardia:
2) sustained polymorphic ventricular tachycardia: 3) ven-
tricular fibrillat ion; and 4) reproducibly inducible nonsus-
tained monomorphic ventricular tachycardia that was not
initiated during the baseline study.
Statistical methods. Continuous variables were reported
as the mean ± SEM. Comparisons between normally dis-
tributed continuous variables were made using two-tailed
t tests with appropriately chosen variances. Nonnormally
distributed continuous variables were analyzed by the Wil-
coxon nonpaired rank sum test. Comparisons between dis-
crete variables were done by the Fisher exact test. The
statistical test used to derive each probability value is iden-
tified in the given table.
Results
Baseline study. Baseline programmed ventricular stim-
ulation in the 24 study patients induced a maximal response
of 0 to 3 beats in 14 patients, 4 to 5 beats in 5 patients and
nonsustained polymorphic ventricular tachycardia of 6 to
16 beats in 5 patients. The induction of nonsustained poly-
morphic ventricular tachycardia required two ventricularex-
trastimuli in one patient and three ventricular extrastimuli
in four patients.
Frequency of proarrhythmic responses during drug
testing. During the 55 prospective drug trials performed in
the 24 patients. six proarrhythmic responses occurred in six
Figure I. Induction of ventricular tachycardia during procain-
amide therapy. During the control study (top panel). a maximum
of two repetitive ventricular responses were induced with triple
extrastimuli ( S~S1S4 ) ' After testing with procainamide (lower panel) ,
sustained monomorphic ventricular tachycardia was induced. In
each panel. from top to bottom are leads YI, I. aYF (F) and an
intracardiac electrogram recorded from the right ventricle (RY).
CL = cycle length. Heavy time lines represent I second.
BASELINE
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Figure 3. Induction of ventricular fibrillation during quinidine
therapy. During thecontrol study (top panel), a maximum of two
repetitive ventricular beats were induced. After testing with quin-
idine (lower panel), burst pacing at a cycle length of 350 ms
induced sustained polymorphic ventricular tachycardia that de-
generated into ventricular fibrillation. Note that the onset of this
arrhythmia is preceded by a pause of 1.5 seconds interrupted by
a sinus beat. The patient also had a spontaneous episode of sus-
tained ventricular fibrillation I hourafterthestudy was completed.
Recording format and abbreviations as in Figure I (see text for
details).
transmural myocardial infarction 6, 14 and 21 months, re-
spectively, before entry into the study. One patient with
congestive cardiomyopathy (Patient 6) had induction of ven-
tricular fibrillation during testing with quinidine; this oc-
curred in association with prolongation of the QTc interval
to 575 ms from a baseline of 470 ms. This arrhythmia was
reproducibly induced by burst pacing on two different oc-
casions during the same study, and on both occasions its
onset was preceded by a long pause interrupted by a sinus
beat (Fig. 3). One hour after completion of electrophar-
macologic testing, the patient had a spontaneous episode of
sustained torsade de pointes requiring resuscitation and de-
fibrillation. The remaining patient (Patient 4) with inducible
nonsustained monomorphic ventricular tachycardia had
moderate left ventricular hypertrophy secondary to systemic
hypertension.QUINIDINE 3.5mcg/ml
F
VI
F
Figure 2. Provocation of sustained monomorphic ventricular
tachycardia during quinidine therapy. During thecontrol study (top
panel), nonsustained polymorphic ventricular tachycardia with a
maximal duration of eight beats was induced. Retesting with quin-
idine induced sustained monomorphic ventricular tachycardia. Re-
cording format and abbreviations as in Figure I.
different patients (Group I). Thus, 25% of the patients (6
of 24) had a proarrhythmic response to one class IA anti-
arrhythmic drug, and II % of drug trials (6 of 55) led to a
proarrhythmic response (Table I). These responses included
induction of sustained monomorphic ventricular tachycardia
in three patients (Fig. I and 2), ventricular fibriIlation in
two patients (Fig. 3) and reproducibly inducible nonsus-
tained monomorphic ventricular tachycardia in one patient.
Induction of the proarrhythmic responses required three ven-
tricular extrastimuli in five patients and burst pacing in one.
Proarrhythmic responses were caused by quinidine in three
patients (sustained ventricular tachycardia in two, ventric-
ular fibrillation in one), procainamide in two patients (sus-
tained ventricular tachycardia in one, ventricular fibriIlation
in one) and disopyramide in one patient (nonsustained
monomorphic ventricular tachycardia). Five of the six Group
I patients underwent testing with one (three patients) or two
(two patients) other class IA antiarrhythmic drugs but did
not show additional proarrhythmic responses (Table 2).
Five of the six Group I patients had underlying heart
disease. All three patients (Patients I to 3) with inducible
sustained monomorphic ventricular tachycardia had had a
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Table 2. Characteristics of Proarrhythm ic Responses in the Six Group I Patients
RY ERP Drugs
Proarrhythmic Response Proarrh Blood Blood
Baseline CI Baseline Drug Proarrh Level Other Drugs Level
Case Dx Response Type Morph (m s) (rns) (ms) %Change Drug (/-Lg/ml) Tested ( /-Lg/ml)
CAD 2 RYR SMYT RBBB. 350 220 230 4.5 Proc 11 .6 None
LAD
2 CAD NSPVT SMVT RBBB. 300 220 240 9.1 Quin 3.5 Proc, 8.5
(8 RYR) LAD diso 7.1
3 CAD NSPYT SMVT LBBB. 290 230 240 4.3 Quin 4.9 Proc 12.5
(6 RYR) LAD
4 HHD 2 RVR NSMVT LBBB. 300 230 250 8.7 Diso 6.0 Proc, 12.2
(12 RVR) RAD quin 5.0
5 "N ormal" NSPVT YF 170 210 210 0 Proc 4.5 Quin 1.2
heart (16 RVR)
6 CCM 2 RYR YF 230 280 22 Quin 2.1 Proc 13.0
CAD = coronary artery disease; CCM = congestive cardiomyopathy;CI = cycle length; diso = disopyramide; Dx = diagnosis; HHD = hypertensive
heart disease; LAD = left axis deviation; LBBB = left bundle branch block; Morph = morphology; NSPVT = nonsustained polymorphic ventricular
tachycardia; Proarrh = proarrhythrnic; Proc = procainamide; Quin = quinidine; RAD = right axis deviation; RBBB = right bundle branch block; RY
ERP = right ventricular effective refractory period during 500 ms ventricular cycle drive; RYR = repetitive ventricular response; SMVT = sustained
monomorphic ventricular tachycardia; YF = ventricular fibrillation: %Change = percent increase in effective refractory period.
None of the 24 study patients demonstrated clinical or
electrocardiographic evidence of antiarrhythmic drug tox-
icity, and serum antiarrhythmic drug levels were within the
accepted therapeutic range (Tables I and 2).
Comparison of patients with versus those without
proarrhythmic responses. The six Group I patients were
compared with the other 18 patients (Group II) with respect
to their clinical characteristics (Table 3). Four of the six
Group I patients were taking digoxin compared with only
2 of the 18 Group II patients (p < 0.02). Group I patients
tended to have a higher prevalence of previous myocardial
infarction compared with Group II patients (50% versus
11 %, P < 0.08). The two groups did not differ significantly
with regard to age, sex, functional class, presence of hy-
pertension or type of heart disease. There was no significant
difference in the mean hourly frequency of ventricular pre-
mature beats or presence of repetitive ventricular premature
beats on 24 hour ambulatory electrocardiographic monitor-
ing.
The baseline ventricular effective refra ctory period mea-
sured at the right ventricular apex was significantly shorter
in Group I patients than in Group II patients (223 ± 3
versus 242 ± 4 ms, p < 0.01) (Fig. 4). During testing of
their proarrhythmic drugs. Group I patients showed an in-
crement of 8 ± 4% in the effective refractory period com-
pared with an increment of 15 ± I% in Group II patients
(p = 0.06) (Fig. 4). However, the QRS duration and QTc
interval of the two groups were not statistically different at
Table 3. Clin ical Profile of Pat ients With (Group l) or Without (Group II)
Proarrhythmic Responses
Group I Group II
(6 patients) (18 patients) p Value
Age (yr) 55 ± 7 57 ± 3 NS*
NYHA
Class I 1(17%) 11 (61%) NSt
Class II to III 5(83%) 7(39%) Ns t
Hypertension 4(67%) 8(44%) NSt
Prior MI 3(50%) 2(11%) < O.08t
Digoxin 4(67%) 2(\ 1%) < O.02t
YPBs/h (range) 307 ± 84 366 ± 87 NS:j:
(15 to 581) (]Oto 1196)
Repetitive YPBs 4(67%) 13(72%) NSt
*Two-tailed I test equal variances: t Fisher' s exact test; :j:Wilcoxon nonpairedrank sum test. MI = myocardial
infarction; NS = not significant: NYHA = New York Heart Association functional class; repetitive YPBs =
two to five consecutive ventricular beats during ambulatory electrocardiographic monitoring.
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Figure 4, Comparisonof drug-induced incre-
mentsineffective refractory period(ERP),QRS
duration and QTc intervals of patients with
(Group I) and without (Group II) a proar-
rhythmic response. As compared with Group
II patients, patients in Group I had a signifi-
cantly shorter baselineeffective refractory pe-
riod and a smaller increment in effective re-
fractory period after antiarrhythmic drug
administration. See text for statistical results.
PTS = patients;QTc = correctedQT interval.
baseline or during drug testing. During the control study,
the sinus cycle length was shorter in Group I than in Group
II patients (690 ± 55 versus 847 ± 32 ms, p < 0.02). In
Group I patients, sinus cycle length was 650 ± 27 ms after
procainamide (p = NS), 656 ± 29 ms after quinidine
(p = NS) and 730 and 780 ms, respectively, after diso-
pyramide. The sinus cycle length in Group II patients was
753 ± 23 ms after procainamide (p < 0.05), 778 ± 20
ms after quinidine (p = 0.09) and 805 ± 29 ms (p = NS)
after disopyramide.
Follow-up, Of the six Group I patients, two were dis-
charged receiving procainamide and flecainide, respec-
tively, for control of symptomatic ventricular premature
beats; both patients had shown a proarrhythmic response
during programmed ventricular stimulation with quinidine.
The remaining four Group I patients received no antiar-
rhythmic therapy. During a mean follow-up period of 8.2 ±
0.8 months (range 6 to 18), all have stayed free of spon-
taneous sustained ventricular tachycardia or sudden cardiac
arrest, with the exception of Patient 3, who developed sud-
den nonfatal cardiac arrest after being started on tocainide
therapy (1,200 mg/day) by her private physician. This pa-
tient had shown a proarrhythmic response to quinidine in
the laboratory (sustained monomorphic ventricular tachy-
cardia), and subsequent treatment with f1ecainide and amio-
darone also resulted in incessant ventricular tachycardia re-
quiring multiple defibrillations. She received an automatic
implantable defibrillator 6 months after the initial electro-
physiologic testing and, while taking no antiarrhythmic drugs,
has had no shock delivered in an 8 month follow-up period.
None of the 18 Group 11 patients were discharged on
antiarrhythmic therapy. One patient was lost to follow-up
at 1 month. Subsequently, two patients had to be treated
with flecainide and one with procainamide for intolerable
symptoms of palpitation. During a follow-up period of 9.5
± 0.8 months (range 7 to 14), none has developed spon-
taneous sustained ventricular tachycardia or sudden death,
although the majority have continued to experience occa-
sional episodes of palpitation.
Discussion
Proarrhythmic effects of antiarrhythmic drugs. Our
results show that in patients with frequent ventricular pre-
mature beats but no sustained ventricular arrhythmias, class
IA antiarrhythmic drugs caused a proarrhythmic response
during programmed ventricular stimulation in 6 (11%) of
the 55 prospective drug trials and in 6 (25%) of the 24
patients. A proarrhythmic response to one drug did not
predict a similar response to a different drug of the same
class.
These findings are comparable with those of several pre-
vious studies (9-12) of patients with sustained ventricular
arrhythmias in which drug-induced proarrhythmic responses
occurred in about 15% of the patients during ambulatory
electrocardiographic monitoring or programmed ventricular
stimulation. However, the criteria we used to define a proar-
rhythmic response and our patient group differed from those
of the previous studies. Velebit et al. (12) retrospectively
studied 155 patients, more than 75% of whom presented
with sudden cardiac arrest or sustained ventricular tachy-
cardia, and reported aggravation of ventricular arrhythmias
in II % of the 722 drug trials evaluated by ambulatory
electrocardiographic monitoring. However, in patients with
clinical ventricular tachycardia undergoing ambulatory
electrocardiographic monitoring, there is significant short-
term spontaneous variability in the frequency and complex-
ity of ventricular premature beats and in the frequency of
sustained or nonsustained ventricular tachycardia (13-15).
Thus, it is difficult to determine whether the augmented
arrhythmias were due to proarrhythmic effects or merely
represented spontaneous variability of the arrhythmias. Other
recent studies (10,11) in patients with recurrent sustained
ventricular arrhythmias suggested that antiarrhythmic drugs
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caused aggravation of arrhythmias during electropharma-
cologie testing in 13 to 16% of drug trials. In both studies.
a less aggressive mode of induction of ventricular tachy-
cardia during antiarrhythmic drug testing was considered to
represent a proarrhythmic effect of the drug and accounted
for nearly one-half of all proarrhythmic responses reported.
However, there is no general agreement on this criterion
because several studies (16-19) have shown that in patients
with inducible sustained ventricular tachycardia, the mode
of ventricular tachycardia induction (number of ventricular
extrastimuli, paced cycle length, stimulation location) varies
spontaneously from day to day. In our study. we did not
consider a change in the induction mode to represent a
proarrhythmic effect. None of our patients had ventricular
tachycardia by history or 24 hour ambulatory electrocar-
diographic monitor or during baseline programmed ventric-
ular stimulation using up to three ventricular extrastimuli.
Nonetheless, even in this group of patients, we demonstrated
proarrhythmic effects of antiarrhythmic drugs in II % of
drug trials and 25% of the patients.
Criteria of proarrhythmic response during pro-
grammed ventricular stimulation. When using pro-
grammed ventricular stimulation to evaluate drug-induced
arrhythmias, it is difficult to be certain if the induced ar-
rhythmias represent random variability of the induced re-
sponse or if they are indeed caused by the antiarrhythmic
agent. The reproducibility of induced response with the
stimulation protocol similar to that used in our study has
varied between 87% and 100% (18-20). Bigger et al. (20)
performed two baseline studies 4 days apart in 52 patients
with a history of sustained ventricular tachycardia; their
stimulation protocol consisted of triple extrastimuli and burst
pacing delivered at two right ventricular sites and two paced
cycle lengths. Of 47 patients with inducible sustained ven-
tricular tachycardia at the first study, 41 (87%) had the same
arrhythmia induced during the second study. The remaining
six patients had induction of nonsustained ventricular tachy-
cardia (three patients) or no ventricular tachycardia (three
patients). The reproducibility of induced response has been
lower (43% to 56%) when a single right ventricular site was
stimulated at one paced cycle length (21,22). Duff et al.
(21) reported a low reproducibility (43%) of the induced
response when the electrode catheter was left in place for
the repeat stimulation study. However, when the electrode
catheter was repositioned for the second study, the repro-
ducibility of induced response was 100%. In all 24 patients
in our study, we stimulated two right ventricular sites at
two paced cycle lengths for each programmed stimulation
test both before and after administration of antiarrhythmic
agents, and therefore, the development of proarrhythmic
responses in 25% of our patients is unlikely to be merely a
manifestation of lack of reproducibility of the induced re-
sponse to programmed stimulation. Moreover. five of the
six patients showing a proarrhythmic response underwent
seven additional drug trials without induction of ventricular
tachycardia or fibrillation.
We did not consider nonsustained polymorphic ventric-
ular tachycardia as a positive response because stimulation
with triple extrastimuli has been shown to induce this ar-
rhythmia in up to 50% of patients with no previous history
of ventricular tachycardia (23-27). On the other hand, non-
sustained or sustained monomorphic ventricular tachycardia
is almost never induced in patients with no prior history of
ventricular tachycardia, and induction of ventricular fibril-
lation in such patients is also an infrequent finding, occurring
in 0 to 10% of the studied patients (23,26,27). We did not
include patients with recent «4 months) myocardial in-
farction because programmed ventricular stimulation in the
survivors of acute myocardial infarction has been demon-
strated to induce sustained ventricular tachycardia or ven-
tricular fibrillation in 17% to 46% of the studied patients,
and only a small minority of patients with inducible tachy-
arrhythmia had subsequent occurrence of spontaneous sus-
tained ventricular tachycardia or sudden death (28-30). None
of our 24 patients had induction of monomorphic ventricular
tachycardia or ventricular fibrillation during the baseline
study; therefore, the induction of these arrhythmias during
repeat study while taking an antiarrhythmic agent most likely
represented the proarrhythmic effects of the drug. Previous
data from trials of encainide (31) suggested that there may
be a correlation between aggravation of electrically induced
arrhythmia and recurrence of spontaneous arrhythmia during
treatment with antiarrhythmic agents. Our follow-up data
support this contention in that two of the six Group I patients
(Patients 3 and 6) had clinical occurrence of sustained ven-
tricular tachyarrhythmias while taking an antiarrhythmic drug;
these arrhythmias were similar in configuration to those
induced during programmed ventricular stimulation. Both
patients have continued to do well without any antiarrhyth-
mic therapy during a follow-up period of 8 and 14 months,
respectively.
Potential mechanisms of proarrhythmic effects. The
mechanism by which a class IA antiarrhythmic drug causes
ventricular arrhythmias is unknown. Termination of a reen-
trant arrhythmia by an antiarrhythmic drug is achieved when
the effective refractory period in tissues proximal to the site
of reentry is prolonged sufficiently so that a returning wave
front, despite slowed conduction, still finds those tissues
refractory (32,33). Conceivably, if an antiarrhythmic drug
were to minimally affect refractoriness but still prolong im-
pulse conduction time. then areas of the reentrant pathway
might recover sufficiently to allow the returning wave front
to continue and perpetuate the reentrant arrhythmia. That
this mechanism might have been operative in our patients
was supported by the observation that the patients with
proarrhythmic responses (Group I) had a significantly shorter
396 AU ET AL.
DRUG-INDUCED ARRHYTHMIAS DURING ELECTROPHYSIOLOGIC TESTING
JACe VoL 9, No.2
February 1987:389 ~97
baseline effective refractory period and a smaller increment
in effective refractory period while taking a proarrhythmic
drug despite achieving a serum drug concentration in the
high therapeutic range. This was more evident in the four
patients with drug-induced monomorphic ventricular tachy-
cardia whose mean effective refractory period was increased
by only 6.6% (Table 2). Drug-induced increments in QRS
duration (reflecting impulse conduction time) did not differ
between the two groups, However, these electrophysiologic
measurements are, at best, an indirect and gross estimate
of the changes in cellular electrophysiologic properties of
the reentrant circuit, and a true understanding of drug-in-
duced arrhythmias must await precise definition of the basis
for therapeutic action of antiarrhythmic drugs.
Limitations. This study has certain limitations. Because
the six Group I patients were not rechallenged on the drug
that was proarrhythmic during programmed ventricular
stimulation, it is not known whether they would have ex-
perienced similar arrhythmias while taking these drugs clin-
ically. A definitive answer to this question will require treat-
ing these patients with the antiarrhythmic drug shown to be
proarrhythmic during programmed ventricular stimulation
and monitoring them closely for development of proar-
rhythmic effects. Clinically, there was no justification for
continuing a patient without a history of ventricular tachy-
cardia on treatment with a drug suspected of being arrhyth-
mogenic. Because none of our patients underwent ambu-
latory electrocardiographic monitoring or exercise testing
during antiarrhythmic drug therapy, we do not know whether
ambulatory monitoring would have been equally efficacious
in detecting proarrhythrniceffects of the antiarrhythmicagents,
or whether there was any concordance between the two
methods (programmed ventricular stimulation versus am-
bulatory monitoring) in detecting proarrhythmic effects. Also,
in all six Group I patients with proarrhythmic responses,
stimulation with triple extrastimuli or burst pacing mode
was required to induce the proarrhythmic event. It is possible
that aggressiveness of the stimulation protocol contributed
to induction of these arrhythmias, which might not have
otherwise manifested during long-term antiarrhythmic ther-
apy. However, two of these six patients (Patients 3 and 6)
had the clinical occurrence of similar arrhythmias during
the follow-up period while taking antiarrhythmic agents.
Finally, it would have been desirable to perform two
baseline tests in each patient to address the issue of repro-
ducibility of the induced response to programmed ventric-
ular stimulation. It is difficult to justify multiple studies in
these patients who had no prior history of suspected or
documented clinical ventricular tachycardia. These patients
had been referred to the electrophysiologic service because
the physicians in charge of the patients had perceived a
clinical problem that needed resolution and one programmed
ventricular stimulation test seemed reasonable. The issue of
reproducibility of the induced response in our patients was
also addressed earlier in the Discussion section.
Clinical implications. The present study is the first to
prospectively examine the proarrhythmic effects of antiar-
rhythmic drugs during programmed ventricular stimulation
in patients with frequent ventricular premature beats but no
sustained ventricular arrhythmias, and it emphasizes the
potential risk of antiarrhythmic drug therapy in such pa-
tients. Twenty-five percent of the patients had a proar-
rhythmic response. The incidence of induced proarrhythmic
responses (11% of drug trials, 25% of patients) reported by
us is similar to that reported by others who were studying
different patient populations (10-12). These findings stress
the need for a careful assessment of potential risks and
benefits of antiarrhythmic agents when treating patients with
ventricular arrhythmias of uncertain prognostic significance,
We acknowledge the expert technical assistance of Judith Clarke, RN and
Sharon Blue, RN.
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